Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Jan Moritz Middeke, Friedrich Stölzel et al.|Blood Cancer Journal|2021Cited by 65
Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trialKristina Hölig, Johannes Schetelig, Helmuth Schmidt et al.|Bone Marrow Transplantation|2020Cited by 23
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patientsChristina Rautenberg, Friedrich Stölzel, Jan Moritz Middeke et al.|Blood Cancer Journal|2025Cited by 6
Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trialKristina Hölig, Johannes Schetelig, Helmuth Schmidt et al.|Bone Marrow Transplantation|2021Cited by 0
S225: ALLOGENEIC STEM CELL TRANSPLANTATION FOR NK/T-CELL LYMPHOMA IN THE ERA OF ASPARAGINASE-BASED CHEMOTHERAPY: A RETROSPECTIVE ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTYPhilipp Berning, Bertram Glaß, Arnaud Jaccard et al.|HemaSphere|2023Cited by 0